Is capecitabine efficacious in triple negative metastatic breast cancer?
Oncology, 03/24/2011
Clinical Article
Kotsori AA et al. – Capecitabine is a treatment option for patients with TN tumours in advanced disease including 1st line and 2nd/3rd line.
Methods- All TNT patients on prospectively maintained database
- Locally advanced or metastatic breast cancer
- Given capecitabine as 1st-, 2nd- or 3rd-line chemotherapy
- Assessed for response and outcome
- 363 patients with locally advanced or metastatic breast cancer treated with capecitabine identified
- 89 (24.5%) patients had TNT and of these, 47 (53%) patients received capecitabine as 1st-line treatment and 42 (47%) as 2nd- or 3rd-line treatment
- ORR 21% (95% CI: 13–31%), including 1 (1%) CR and 18 (20%) PR
- Another 11 (12%) patients maintained stable disease (SD) for 6 months
- Overall disease control (CR + PR + SD) achieved in 30 (33%) patients
- Median time to disease progression 11 weeks (95% CI: 9–13) and median OS 39 weeks (95% CI: 33–45)
- Median response duration 22 weeks (95% CI: 18–25)
- No significant difference in efficacy seen between 1st- and 2nd-/3rd-line treatment
